Halozyme Therapeutics, Inc. (HALO)
109.86
+2.92
(+2.73%)
USD |
NASDAQ |
Oct 02, 16:00
109.79
-0.07
(-0.06%)
After-Hours: 20:00
Halozyme Therapeutics Gross Profit Margin (Quarterly) : 77.40% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 77.40% |
| March 31, 2026 | 71.13% |
| December 31, 2025 | 77.39% |
| September 30, 2025 | 79.39% |
| June 30, 2025 | 80.31% |
| March 31, 2025 | 75.02% |
| December 31, 2024 | 79.93% |
| September 30, 2024 | 76.84% |
| June 30, 2024 | 75.20% |
| March 31, 2024 | 76.47% |
| December 31, 2023 | 69.54% |
| September 30, 2023 | 65.21% |
| June 30, 2023 | 69.28% |
| March 31, 2023 | 67.31% |
| December 31, 2022 | 74.28% |
| September 30, 2022 | 64.34% |
| June 30, 2022 | 70.24% |
| March 31, 2022 | 86.42% |
| December 31, 2021 | 78.84% |
| September 30, 2021 | 83.95% |
| June 30, 2021 | 83.13% |
| March 31, 2021 | 79.53% |
| December 31, 2020 | 78.41% |
| September 30, 2020 | 91.48% |
| June 30, 2020 | 89.61% |
| Date | Value |
|---|---|
| March 31, 2020 | 77.18% |
| December 31, 2019 | 68.91% |
| September 30, 2019 | 51.69% |
| June 30, 2019 | 92.65% |
| March 31, 2019 | 91.84% |
| December 31, 2018 | 90.67% |
| September 30, 2018 | 97.55% |
| June 30, 2018 | 97.63% |
| March 31, 2018 | 90.11% |
| December 31, 2017 | 96.05% |
| September 30, 2017 | 86.93% |
| June 30, 2017 | 76.92% |
| March 31, 2017 | 74.49% |
| December 31, 2016 | 79.48% |
| September 30, 2016 | 71.32% |
| June 30, 2016 | 75.08% |
| March 31, 2016 | 81.74% |
| December 31, 2015 | 83.86% |
| September 30, 2015 | 70.26% |
| June 30, 2015 | 81.23% |
| March 31, 2015 | 65.21% |
| December 31, 2014 | 79.76% |
| September 30, 2014 | 64.80% |
| June 30, 2014 | 67.78% |
| March 31, 2014 | 53.87% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| AVITA Medical, Inc. | 81.87% |
| Iovance Biotherapeutics, Inc. | 46.54% |
| Incyte Corp. | 92.57% |
| BioCryst Pharmaceuticals, Inc. | 98.01% |
| Neurocrine Biosciences, Inc. | 95.87% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 165.6% |
| Return on Assets | 16.90% |
| Return on Invested Capital | 19.26% |
| Profit Margin (Quarterly) | 47.80% |
| Operating Margin (Quarterly) | 59.80% |
| Return on Net Operating Assets | 21.91% |